SESSION TITLE: Airways 5
SESSION TYPE: Original Investigation Poster
PRESENTED ON: Wednesday, October 26, 2016 at 01:30 PM - 02:30 PM
PURPOSE: Reducing exacerbations is a key goal of COPD treatment due to their detrimental effects on lung function and health status. The Phase III, TONADO studies assessed efficacy and safety of tiotropium + olodaterol (T+O) in patients with moderate to very severe COPD. We investigated if GOLD stage and baseline ICS use are prognostic for the number of patients with, and time to first, COPD exacerbation, irrespective of treatment arm.